| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT |
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-16 13:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT |
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-14 13:00:00 |
Czytaj oryginał (ang.) |
| Did PTC Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - PTCT |
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients. |
accessnewswire.com |
2025-05-13 16:25:00 |
Czytaj oryginał (ang.) |
| PTC Inc. (PTC) is a Top-Ranked Momentum Stock: Should You Buy? |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-05-13 14:55:44 |
Czytaj oryginał (ang.) |
| Investors Who Lost Money on PTC Therapeutics, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - PTCT |
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announcing results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients. |
accessnewswire.com |
2025-05-12 21:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT |
NEW YORK , May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-05-12 21:07:00 |
Czytaj oryginał (ang.) |
| PTC Inc. (PTC) is a Top-Ranked Growth Stock: Should You Buy? |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-05-12 14:50:50 |
Czytaj oryginał (ang.) |
| PTC Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- PTCT |
NEW YORK, NY / ACCESS Newswire / May 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients. |
accessnewswire.com |
2025-05-11 15:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT |
NEW YORK CITY, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-10 12:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT |
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. |
globenewswire.com |
2025-05-09 14:37:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT |
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-08 12:00:00 |
Czytaj oryginał (ang.) |
| uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data |
uniQure's lead program for Huntington's Disease is planning to file an application via the accelerated approval pathway. On Monday, May 5th, PTC Therapeutics announced positive results from their phase 2 Huntington's Disease trial. I compare the data from these two treatments and share my thoughts here. |
seekingalpha.com |
2025-05-08 09:16:15 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT |
NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-05-07 12:00:00 |
Czytaj oryginał (ang.) |
| An Investigation Has Commenced on Behalf of PTC Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your PTCT Losses |
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients. |
accessnewswire.com |
2025-05-06 23:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT |
NEW YORK , May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-05-06 22:50:00 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results |
– Strong revenue performance of $190 million – – Positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025, NDA review remains on track for July 29, 2025 PDUFA date – – Global Sephience launch activities progressing well – – Strong cash position of over $2.0 billion as of March 31, 2025 – WARREN, N.J. , May 6, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ended March 31, 2025. |
prnewswire.com |
2025-05-06 20:01:00 |
Czytaj oryginał (ang.) |
| Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? |
PTC Therapeutics, Inc. PTCT on Monday announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients. |
benzinga.com |
2025-05-05 20:54:20 |
Czytaj oryginał (ang.) |
| PTC518 PIVOT-HD Study Achieves Primary Endpoint |
- Study met primary endpoint with dose-dependent blood HTT protein lowering at Week 12 - - Favorable dose-dependent trends across clinical scales in Stage 2 patients at Month 12 - - Signals of dose-dependent clinical benefit relative to matched natural history cohort as well as dose-dependent lowering of NfL in Stage 2 patients at Month 24 - - Continued favorable safety and tolerability profile with no treatment-related NfL spikes - - PTC will host a conference call on May 5, 2025, at 8:00 am ET- WARREN, N.J. , May 5, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients. |
prnewswire.com |
2025-05-05 11:00:00 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WARREN, N.J. , May 1, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that on April 25, 2025, the company approved non-statutory stock options to purchase an aggregate of 7,000 shares of its common stock and 10,780 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 12 new employees. |
prnewswire.com |
2025-05-01 20:30:00 |
Czytaj oryginał (ang.) |
| PTC's Q2 Earnings & Revenues Top, Improve Y/Y, 2025 Outlook Tweaked |
PTC's Q2 performance is driven by solid recurring revenues amid a tough sales backdrop. Fiscal 2025 view is revised based on potential macro volatility. |
zacks.com |
2025-05-01 13:50:44 |
Czytaj oryginał (ang.) |
| PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
WARREN, N.J. , Dec. 23, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B. |
prnewswire.com |
2024-12-23 10:00:00 |
Czytaj oryginał (ang.) |
| This Software Stock Could Be the Best Investment of the Decade |
Every consumer knows about the growing role of artificial intelligence (AI) and wirelessly enabled digital technologies in our daily lives. But not everyone knows about the seismic shift these developments are having on the manufacturing industry and the role that an industrial software company like PTC (PTC 0.24%) is playing in it. |
fool.com |
2024-12-21 06:54:00 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia |
- If approved, vatiquinone would be the first and only authorized therapy for children with FA - - PTC's fourth approval application submitted to FDA in 2024 - WARREN, N.J. , Dec. 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) for the treatment of children and adults living with Friedreich ataxia (FA) to the U.S. Food and Drug Administration (FDA). |
prnewswire.com |
2024-12-19 10:00:00 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WARREN, N.J. , Dec. 17, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 13, 2024, the company approved non-statutory stock options to purchase an aggregate of 1,725 shares of its common stock and 5,060 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to eight new employees. |
prnewswire.com |
2024-12-17 18:30:00 |
Czytaj oryginał (ang.) |
| PTC Appoints Robert Dahdah as Executive Vice President, Chief Revenue Officer |
BOSTON , Dec. 9, 2024 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that it has appointed Robert Dahdah as Executive Vice President, Chief Revenue Officer. Dahdah joins PTC from Microsoft, where he served as Corporate Vice President of Global Healthcare and Life Sciences. |
prnewswire.com |
2024-12-09 10:30:00 |
Czytaj oryginał (ang.) |
| Why Is PTC Inc. (PTC) Up 5.7% Since Last Earnings Report? |
PTC Inc. (PTC) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-12-09 08:48:54 |
Czytaj oryginał (ang.) |
| PTC, Microsoft & Volkswagen Collaborate on Codebeamer AI Copilot |
PTC partners with MSFT and Volkswagen for a Codebeamer AI Copilot designed to simplify product development. |
zacks.com |
2024-12-05 11:30:27 |
Czytaj oryginał (ang.) |
| PTC Partners with Microsoft and Volkswagen Group to Develop Codebeamer Generative AI Copilot |
Collaboration brings together industry leaders to advance generative AI use cases for manufacturing Codebeamer Copilot expected to simplify requirements management as part of the product development process Codebeamer Copilot beta expected to release in early 2025 BOSTON , Dec. 3, 2024 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that it has partnered with Microsoft and Volkswagen Group to develop a generative artificial intelligence (AI) copilot based on the PTC Codebeamer® application lifecycle management (ALM) solution. Codebeamer Copilot will support software development in physical products by enabling software engineers to create and manage product requirements more efficiently as well as test, validate, and release them. |
prnewswire.com |
2024-12-03 10:30:00 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Stock Soars on Novartis Licensing Agreement |
Shares of PTC Therapeutics (PTCT) soared 16% Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and collaboration deal with Novartis (NVS). |
investopedia.com |
2024-12-02 15:50:44 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program |
On Monday, PTC Therapeutics, Inc. PTCT signed an exclusive global license and collaboration agreement with Novartis AG NVS for its PTC518 Huntington's disease program, which includes related molecules. |
benzinga.com |
2024-12-02 14:58:49 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone |
Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged. |
investors.com |
2024-12-02 11:32:47 |
Czytaj oryginał (ang.) |
| PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis |
PTC Therapeutics has entered into a licensing deal with a unit of Novartis AG for up to $1.9 billion, the company said on Monday, for its experimental drug being developed for a rare neurological disorder. |
reuters.com |
2024-12-02 09:14:56 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program |
- PTC to receive $1.0B in cash at closing - - PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones - - PTC to share profits in the U.S. and tiered double-digit royalties on ex-U.S. net sales - - Novartis will assume global development, manufacturing and commercial responsibilities following completion of placebo-controlled portion of ongoing PIVOT-HD study - - PTC will host a conference call on Dec. 2, 2024, at 8:30 am EST- WARREN, N.J. , Dec. 2, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE: NVS), for its PTC518 Huntington's disease program, which includes related molecules. |
prnewswire.com |
2024-12-02 09:00:00 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs |
On Tuesday, PTC Therapeutics Inc PTCT revealed data from the global Phase 2 placebo-controlled CardinALS study of Utreloxastat in amyotrophic lateral sclerosis patients. |
benzinga.com |
2024-11-27 09:51:49 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million |
WARREN, N.J. , Nov. 27, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the transaction. |
prnewswire.com |
2024-11-27 09:00:00 |
Czytaj oryginał (ang.) |
| PTC Therapeutics discontinues development of ALS drug after trial failure |
PTC Therapeutics said on Tuesday it is discontinuing the development of its drug for a type of fatal neurodegenerative disease, as it did not meet the main goal in a mid-stage trial. |
reuters.com |
2024-11-26 18:41:10 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients |
- Study failed to meet primary and secondary efficacy endpoints - WARREN, N.J. , Nov. 26, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing disease progression on the composite ALSFRS-R and mortality analysis. |
prnewswire.com |
2024-11-26 18:30:00 |
Czytaj oryginał (ang.) |
| PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WARREN, N.J. , Nov. 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 20, 2024, the company approved non-statutory stock options to purchase an aggregate of 18,815 shares of its common stock and 17,995 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to ten new employees. |
prnewswire.com |
2024-11-25 18:30:00 |
Czytaj oryginał (ang.) |
| A Few Years From Now, You'll Wish You'd Bought This Undervalued Stock |
A Few Years From Now, You'll Wish You'd Bought This Undervalued Stock |
fool.com |
2024-11-21 06:14:00 |
Czytaj oryginał (ang.) |
| US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder |
The U.S. Food and Drug Administration approved PTC Therapeutics' gene therapy that is administered directly in the brain to treat a potential fatal enzyme deficiency disorder, the company said on Wednesday. |
reuters.com |
2024-11-13 20:09:52 |
Czytaj oryginał (ang.) |